Widespread use (75%) of GLP-1 RAs in the total population with type 2 diabetes was projected to prevent 16,455 MIs, 20,409 strokes, 37,100 HF hospitalisations and 39,917 deaths, but increase the number of ESKD events by 170. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.